Insider Selling: DexCom, Inc. (NASDAQ:DXCM) Insider Sells 5,256 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) insider Andrew K. Balo sold 5,256 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $397.35, for a total transaction of $2,088,471.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Shares of DXCM traded down $4.05 on Wednesday, reaching $393.92. The company’s stock had a trading volume of 641,628 shares, compared to its average volume of 1,299,008. The company has a current ratio of 7.58, a quick ratio of 7.17 and a debt-to-equity ratio of 1.23. DexCom, Inc. has a twelve month low of $145.23 and a twelve month high of $456.23. The stock has a market capitalization of $37.71 billion, a PE ratio of 179.31, a PEG ratio of 3.80 and a beta of 0.81. The firm has a fifty day moving average of $421.38 and a 200-day moving average of $364.11.

DexCom (NASDAQ:DXCM) last posted its earnings results on Tuesday, July 28th. The medical device company reported $0.79 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.31 by $0.48. DexCom had a net margin of 11.93% and a return on equity of 29.01%. The company had revenue of $451.80 million for the quarter, compared to analyst estimates of $415.21 million. During the same quarter in the prior year, the business posted $0.08 EPS. The firm’s revenue was up 34.3% compared to the same quarter last year. As a group, equities analysts anticipate that DexCom, Inc. will post 2.67 EPS for the current fiscal year.

Several brokerages recently weighed in on DXCM. Oppenheimer initiated coverage on shares of DexCom in a research note on Tuesday, July 28th. They issued a “buy” rating and a $445.00 price objective on the stock. SVB Leerink upped their price target on shares of DexCom from $465.00 to $485.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Stifel Nicolaus upped their price target on shares of DexCom from $385.00 to $500.00 and gave the company a “buy” rating in a research report on Wednesday, July 29th. Zacks Investment Research cut shares of DexCom from a “buy” rating to a “hold” rating and set a $430.00 price target on the stock. in a research report on Monday, June 22nd. Finally, UBS Group upped their price target on shares of DexCom from $335.00 to $400.00 and gave the company a “neutral” rating in a research report on Wednesday, July 29th. Seven analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company has an average rating of “Buy” and an average target price of $405.20.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Citizens Financial Group Inc RI raised its holdings in shares of DexCom by 43.8% in the 2nd quarter. Citizens Financial Group Inc RI now owns 92 shares of the medical device company’s stock worth $37,000 after acquiring an additional 28 shares during the last quarter. Gladstone Institutional Advisory LLC raised its holdings in shares of DexCom by 3.6% in the 2nd quarter. Gladstone Institutional Advisory LLC now owns 1,039 shares of the medical device company’s stock worth $421,000 after acquiring an additional 36 shares during the last quarter. Perennial Investment Advisors LLC raised its holdings in shares of DexCom by 5.9% in the 2nd quarter. Perennial Investment Advisors LLC now owns 847 shares of the medical device company’s stock worth $343,000 after acquiring an additional 47 shares during the last quarter. BKD Wealth Advisors LLC increased its stake in DexCom by 1.1% in the 2nd quarter. BKD Wealth Advisors LLC now owns 4,250 shares of the medical device company’s stock valued at $1,723,000 after buying an additional 47 shares during the last quarter. Finally, Stratos Wealth Partners LTD. increased its stake in DexCom by 5.2% in the 2nd quarter. Stratos Wealth Partners LTD. now owns 1,033 shares of the medical device company’s stock valued at $419,000 after buying an additional 51 shares during the last quarter. Institutional investors own 97.51% of the company’s stock.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

See Also: FAANG Stocks

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.